Actualités Bristol Myers Squibb Co - BMY | Actions New York Stock Exchange

Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms

Data from proof-of-concept, randomized, Phase 2 RELATIVITY-104 trial exploring the combination of nivolumab, relatlimab (1:1) and chemotherapy as...

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research

With cancer patients top of mind, teams of Bristol Myers Squibb (NYSE: BMY) employees will relay Coast 2 Coast...

Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Cumulative analysis of data up to 3.5 years from EXPLORER-LTE showed consistent and sustained improvements in echocardiographic measures and...

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in September 2024...

Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024

New analyses, including presentations on CAMZYOS® (mavacamten), ELIQUIS® (apixaban) and milvexian, further solidify the company's strength and...

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

Acceptance based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo (nivolumab) plus Yervoy (ipilimumab...

European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Application based on the TRANSCEND FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety...

Bristol Myers Squibb Reports Second Quarter Financial Results for 2024

Results Underscore Continued Progress on Commercial Execution, Driving the Growth Portfolio and Pipeline Advancement Second Quarter Revenues were...

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

The Application is based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to...

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Virtual Targeted Protein Degradation Day hosted by UBS...

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Approval based on results from the Phase 1/2 KRYSTAL-1 study where KRAZATI in combination with cetuximab showed an objective response rate of 34...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bristol Myers Squibb Co (BMY)

Outils de qualité professionnelle, pour des investisseurs individuels.

BMY Actualités

Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research

Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Reports Second Quarter Financial Results for 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab

Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024

Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors

Bristol Myers Squibb Announces Dividend

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bristol Myers Squibb Co (BMY) Actualités

Bristol Myers Squibb Co (BMY)

Outils de qualité professionnelle, pour des investisseurs individuels.

BMY Actualités

Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research

Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Reports Second Quarter Financial Results for 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab

Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024

Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors

Bristol Myers Squibb Announces Dividend

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application